Skin and Soft Tissue
Skin and Soft Tissue
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
14
Clinical Trials
Skin and Soft Tissue
Phase III
Accepting Patients
nct/study# NCT03712605 / EA6174
STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial
Learn More
Skin and Soft Tissue
Phase II
Accepting Patients
nct/study# NCT04091750 / IST83
Phase II Study of Nivolumab/Ipilimumab plus Cabozantinib in Patients with Unresectable Advanced Melanoma
Learn More
Skin and Soft Tissue
Phase II
Accepting Patients
nct/study# NCT04577807 / LUMINOS-102
PVSRIPO with and without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
Learn More
Skin and Soft Tissue
Phase II
Accepting Patients
nct/study# NCT04768881 / XPORT-MEL-033
A PHASE 2 OPEN-LABEL MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SELINEXOR IN COMBINATION WITH PEMBROLIZUMAB IN ACTIVELY DIAGNOSED OR RECURRENT ADVANCED MELANOMA
Learn More
Skin and Soft Tissue
Phase III
Accepting Patients
nct/study# NCT03486873 / MK3475-587
A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Learn More
Skin and Soft Tissue
Phase III
Accepting Patients
nct/study# NCT03833167 / MK-3475-630
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCCC) (KEYNOTE-630)
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.